192 related articles for article (PubMed ID: 22035199)
1. D(2)-Dopamine receptors target regulator of G protein signaling 9-2 to detergent-resistant membrane fractions.
Celver J; Sharma M; Kovoor A
J Neurochem; 2012 Jan; 120(1):56-69. PubMed ID: 22035199
[TBL] [Abstract][Full Text] [Related]
2. Macromolecular composition dictates receptor and G protein selectivity of regulator of G protein signaling (RGS) 7 and 9-2 protein complexes in living cells.
Masuho I; Xie K; Martemyanov KA
J Biol Chem; 2013 Aug; 288(35):25129-25142. PubMed ID: 23857581
[TBL] [Abstract][Full Text] [Related]
3. RGS9-2 modulates D2 dopamine receptor-mediated Ca2+ channel inhibition in rat striatal cholinergic interneurons.
Cabrera-Vera TM; Hernandez S; Earls LR; Medkova M; Sundgren-Andersson AK; Surmeier DJ; Hamm HE
Proc Natl Acad Sci U S A; 2004 Nov; 101(46):16339-44. PubMed ID: 15534226
[TBL] [Abstract][Full Text] [Related]
4. D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.
Kovoor A; Seyffarth P; Ebert J; Barghshoon S; Chen CK; Schwarz S; Axelrod JD; Cheyette BN; Simon MI; Lester HA; Schwarz J
J Neurosci; 2005 Feb; 25(8):2157-65. PubMed ID: 15728856
[TBL] [Abstract][Full Text] [Related]
5. The complex of G protein regulator RGS9-2 and Gβ(5) controls sensitization and signaling kinetics of type 5 adenylyl cyclase in the striatum.
Xie K; Masuho I; Brand C; Dessauer CW; Martemyanov KA
Sci Signal; 2012 Aug; 5(239):ra63. PubMed ID: 22932702
[TBL] [Abstract][Full Text] [Related]
6. RGS9-2 mediates specific inhibition of agonist-induced internalization of D2-dopamine receptors.
Celver J; Sharma M; Kovoor A
J Neurochem; 2010 Aug; 114(3):739-49. PubMed ID: 20477943
[TBL] [Abstract][Full Text] [Related]
7. A unique role of RGS9-2 in the striatum as a positive or negative regulator of opiate analgesia.
Psifogeorgou K; Terzi D; Papachatzaki MM; Varidaki A; Ferguson D; Gold SJ; Zachariou V
J Neurosci; 2011 Apr; 31(15):5617-24. PubMed ID: 21490202
[TBL] [Abstract][Full Text] [Related]
8. Distribution of RGS9-2 in neurons of the mouse striatum.
Mancuso JJ; Qian Y; Long C; Wu GY; Wensel TG
J Neurochem; 2010 Feb; 112(3):651-61. PubMed ID: 19912469
[TBL] [Abstract][Full Text] [Related]
9. G protein beta 5 is targeted to D2-dopamine receptor-containing biochemical compartments and blocks dopamine-dependent receptor internalization.
Octeau JC; Schrader JM; Masuho I; Sharma M; Aiudi C; Chen CK; Kovoor A; Celver J
PLoS One; 2014; 9(8):e105791. PubMed ID: 25162404
[TBL] [Abstract][Full Text] [Related]
10. RGS9-2 is a negative modulator of mu-opioid receptor function.
Psifogeorgou K; Papakosta P; Russo SJ; Neve RL; Kardassis D; Gold SJ; Zachariou V
J Neurochem; 2007 Oct; 103(2):617-25. PubMed ID: 17725581
[TBL] [Abstract][Full Text] [Related]
11. RGS9 modulates dopamine signaling in the basal ganglia.
Rahman Z; Schwarz J; Gold SJ; Zachariou V; Wein MN; Choi KH; Kovoor A; Chen CK; DiLeone RJ; Schwarz SC; Selley DE; Sim-Selley LJ; Barrot M; Luedtke RR; Self D; Neve RL; Lester HA; Simon MI; Nestler EJ
Neuron; 2003 Jun; 38(6):941-52. PubMed ID: 12818179
[TBL] [Abstract][Full Text] [Related]
12. RGS9-2: probing an intracellular modulator of behavior as a drug target.
Traynor JR; Terzi D; Caldarone BJ; Zachariou V
Trends Pharmacol Sci; 2009 Mar; 30(3):105-11. PubMed ID: 19211160
[TBL] [Abstract][Full Text] [Related]
13. Signal-dependent translocation of transducin, RGS9-1-Gbeta5L complex, and arrestin to detergent-resistant membrane rafts in photoreceptors.
Nair KS; Balasubramanian N; Slepak VZ
Curr Biol; 2002 Mar; 12(5):421-5. PubMed ID: 11882295
[TBL] [Abstract][Full Text] [Related]
14. RGS9 proteins facilitate acute tolerance to mu-opioid effects.
Garzón J; Rodríguez-Díaz M; López-Fando A; Sánchez-Blázquez P
Eur J Neurosci; 2001 Feb; 13(4):801-11. PubMed ID: 11207815
[TBL] [Abstract][Full Text] [Related]
15. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
Xu H; Wang X; Wang J; Rothman RB
Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
[TBL] [Abstract][Full Text] [Related]
16. Activation of mu-opioid receptors transfers control of Galpha subunits to the regulator of G-protein signaling RGS9-2: role in receptor desensitization.
Garzón J; Rodríguez-Muñoz M; López-Fando A; Sánchez-Blázquez P
J Biol Chem; 2005 Mar; 280(10):8951-60. PubMed ID: 15632124
[TBL] [Abstract][Full Text] [Related]
17. Cloning and characterization of RGS9-2: a striatal-enriched alternatively spliced product of the RGS9 gene.
Rahman Z; Gold SJ; Potenza MN; Cowan CW; Ni YG; He W; Wensel TG; Nestler EJ
J Neurosci; 1999 Mar; 19(6):2016-26. PubMed ID: 10066255
[TBL] [Abstract][Full Text] [Related]
18. Regulator of G protein signaling proteins differentially modulate signaling of mu and delta opioid receptors.
Xie Z; Li Z; Guo L; Ye C; Li J; Yu X; Yang H; Wang Y; Chen C; Zhang D; Liu-Chen LY
Eur J Pharmacol; 2007 Jun; 565(1-3):45-53. PubMed ID: 17433292
[TBL] [Abstract][Full Text] [Related]
19. The DEP domain determines subcellular targeting of the GTPase activating protein RGS9 in vivo.
Martemyanov KA; Lishko PV; Calero N; Keresztes G; Sokolov M; Strissel KJ; Leskov IB; Hopp JA; Kolesnikov AV; Chen CK; Lem J; Heller S; Burns ME; Arshavsky VY
J Neurosci; 2003 Nov; 23(32):10175-81. PubMed ID: 14614075
[TBL] [Abstract][Full Text] [Related]
20. Ontogenetic quinpirole treatment produces long-lasting decreases in the expression of Rgs9, but increases Rgs17 in the striatum, nucleus accumbens and frontal cortex.
Maple AM; Perna MK; Parlaman JP; Stanwood GD; Brown RW
Eur J Neurosci; 2007 Nov; 26(9):2532-8. PubMed ID: 17970732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
